OBJECTIVE: To determine the effect of race and ethnicity on the use of oral beta-agonists, inhaled beta-agonists, and inhaled corticosteroids to treat respiratory symptoms in former premature infants after controlling for medical conditions, socioeconomic status, and site of outpatient care. STUDY DESIGN: Using a population cohort of infants born at a gestational age < or = 34 weeks at 5 Northern California Kaiser Permanente hospitals between 1998 and 2001 (n = 1436), we constructed multivariable models to determine predictive factors for the receipt of respiratory medications during the first year after discharge. RESULTS: After controlling for confounding factors, black infants were more likely to receive oral beta-agonists compared with white infants (OR 4.30, 95% CI 2.33-7.94), and Hispanic infants were less likely to receive inhaled beta-agonists (OR 0.62, 95% CI 0.39-0.99) or inhaled corticosteroids (OR 0.28, 95% CI 0.12-0.67). These findings were not explained by more outpatient visits for respiratory symptoms in black or Hispanic infants, because the observed racial differences persisted when children of similar respiratory symptoms were examined. CONCLUSIONS: Even in a high-risk population of insured infants, substantial racial differences persist in the use of respiratory medications that could not be explained by differences in respiratory symptoms.
OBJECTIVE: To determine the effect of race and ethnicity on the use of oral beta-agonists, inhaled beta-agonists, and inhaled corticosteroids to treat respiratory symptoms in former premature infants after controlling for medical conditions, socioeconomic status, and site of outpatient care. STUDY DESIGN: Using a population cohort of infants born at a gestational age < or = 34 weeks at 5 Northern California Kaiser Permanente hospitals between 1998 and 2001 (n = 1436), we constructed multivariable models to determine predictive factors for the receipt of respiratory medications during the first year after discharge. RESULTS: After controlling for confounding factors, black infants were more likely to receive oral beta-agonists compared with white infants (OR 4.30, 95% CI 2.33-7.94), and Hispanic infants were less likely to receive inhaled beta-agonists (OR 0.62, 95% CI 0.39-0.99) or inhaled corticosteroids (OR 0.28, 95% CI 0.12-0.67). These findings were not explained by more outpatient visits for respiratory symptoms in black or Hispanic infants, because the observed racial differences persisted when children of similar respiratory symptoms were examined. CONCLUSIONS: Even in a high-risk population of insured infants, substantial racial differences persist in the use of respiratory medications that could not be explained by differences in respiratory symptoms.
Authors: Rita M Ryan; Roberta L Keller; Brenda B Poindexter; Carl T D'Angio; Pamela A Shaw; Scarlett L Bellamy; Paul E Moore; Christopher McPherson; James M Greenberg Journal: J Pediatr Date: 2019-03-08 Impact factor: 4.406
Authors: J Michael Collaco; SeEun Jennifer Choi; Kristin A Riekert; Michelle N Eakin; Sharon A McGrath-Morrow; Sande O Okelo Journal: Pediatr Pulmonol Date: 2011-02-15
Authors: Scott A Lorch; Michael Baiocchi; Jeffrey H Silber; Orit Even-Shoshan; Gabriel J Escobar; Dylan S Small Journal: Health Serv Res Date: 2009-09-24 Impact factor: 3.402
Authors: Joseph M Collaco; Brianna C Aoyama; Jessica L Rice; Sharon A McGrath-Morrow Journal: Expert Rev Respir Med Date: 2021-06-17 Impact factor: 3.772